Pieter M.
- Country
- Belgium
- Department
- Cardiology
Research Overview
- Efficacy and Safety Evaluation of TX000045 in Pulmonary Hypertension Secondary to Heart Failure with Preserved Ejection Fraction: A Randomized, Placebo-Controlled Study
- Evaluation of Vicadrostat (BI 690517) and Empagliflozin Efficacy and Safety in Patients with Symptomatic Chronic Heart Failure and Reduced Ejection Fraction
- A randomized, double-blind, placebo-controlled, multicentre trial, assessing the impact of ferric carboxymaltose on exercise capacity and functional status in pulmonary hypertension (IRON-PH)
Data & Insights
Has run more than one trial at 7 of 202 partner sites.
Specializations
Cardiovascular Research
This investigator specializes in the clinical study of pulmonary hypertension, with particular emphasis on its relationship to heart failure with preserved ejection fraction (PH-HFpEF).
- Pulmonary Vascular Disease
- Heart Failure Management
- Cardiovascular Hemodynamics
Primary research interests center on evaluating novel therapeutic approaches for patients with complex cardiopulmonary conditions.
Pulmonary Medicine
The investigator focuses on understanding and treating pulmonary vascular resistance in patients with combined cardiac and pulmonary conditions.
- Pulmonary Circulation
- Vascular Resistance Assessment
- Cardiopulmonary Interactions
Specialized expertise includes the evaluation of innovative treatments for pulmonary vascular diseases.
Clinical Therapeutics
Research activities concentrate on investigating therapeutic interventions for complex cardiovascular conditions, particularly in the context of preserved ejection fraction.
- Treatment Efficacy Assessment
- Patient Safety Monitoring
- Clinical Outcomes Research
The investigator evaluates novel therapeutic agents for cardiopulmonary disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.